Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151


Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals.

Paraskevis D, Touloumi G, Bakoyannis G, Paparizos V, Lazanas M, Gargalianos P, Chryssos G, Antoniadou A, Psichogiou M, Panos G, Katsarou O, Sambatakou H, Kordossis T, Hatzakis A; AMACS.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):461-9. doi: 10.1089/AID.2012.0143. Epub 2012 Nov 6.


Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.

Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2011 Dec;53(11):1143-52. doi: 10.1093/cid/cir669. Epub 2011 Oct 13.


Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.

Chaix ML, Seng R, Frange P, Tran L, Avettand-Fenoël V, Ghosn J, Reynes J, Yazdanpanah Y, Raffi F, Goujard C, Rouzioux C, Meyer L; ANRS PRIMO Cohort Study Group.

Clin Infect Dis. 2013 Mar;56(6):880-7. doi: 10.1093/cid/cis999. Epub 2012 Dec 7.


HIV-1 subtypes and response to combination antiretroviral therapy in Europe.

Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A; EuroSIDA Study Group.

Antivir Ther. 2006;11(6):707-15.


The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.

Di Biagio A, Rusconi S, Marzocchetti A, Signori A, Schiavetti I, Bruzzone B, Monno L, Punzi G, Colao MG, Penco G, Zazzi M, De Luca A; ARCA Collaborative Group.

J Med Virol. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017. Epub 2014 Jul 11.


Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort.

Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7.


Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?

Laurichesse JJ, Taieb A, Capoulade-Metay C, Katlama C, Villes V, Drobacheff-Thiebaud MC, Raffi F, Chêne G, Theodorou I, Leport C; ANRS C08 Aproco-Copilote Study Group.

HIV Med. 2010 Apr;11(4):239-44. doi: 10.1111/j.1468-1293.2009.00769.x. Epub 2009 Dec 28.


Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures.

Trotta MP, Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, Vullo V, Soscia F, Chiodera A, Ladisa N, Abeli C, Cauda R, Buonuomi AR, Antinori A, d'Arminio Monforte A; ICONA Foundation Study.

Clin Infect Dis. 2010 Aug 15;51(4):456-64. doi: 10.1086/655151.


Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion.

Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L.

HIV Med. 2007 May;8(4):213-9.


Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.

Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, Parruti G, Galli M, Gori A, Monforte Ad; ICONA Foundation Study.

AIDS. 2013 Mar 13;27(5):769-79. doi: 10.1097/QAD.0b013e32835cb747.


Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort.

Wittkop L, Breilh D, Da Silva D, Duffau P, Mercié P, Raymond I, Anies G, Fleury H, Saux MC, Dabis F, Fagard C, Thiébaut R, Masquelier B, Pellegrin I; ANRS CO3 Aquitaine Cohort.

J Antimicrob Chemother. 2009 Jun;63(6):1251-5. doi: 10.1093/jac/dkp114. Epub 2009 Mar 31.


Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group.

Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.


Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Easterbrook PJ, Smith M, Mullen J, O'Shea S, Chrystie I, de Ruiter A, Tatt ID, Geretti AM, Zuckerman M.

J Int AIDS Soc. 2010 Feb 3;13:4. doi: 10.1186/1758-2652-13-4.


[HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].

Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F; Kliniek en Virologie van het ATHENA-project.

Ned Tijdschr Geneeskd. 2001 Aug 18;145(33):1591-7. Dutch.


Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.


Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

Geretti AM, Harrison L, Green H, Sabin C, Hill T, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance.

Clin Infect Dis. 2009 May 1;48(9):1296-305. doi: 10.1086/598502.


Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B.

Arch Intern Med. 2000 Apr 24;160(8):1123-32.


Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS).

J Antimicrob Chemother. 2013 May;68(5):1169-78. doi: 10.1093/jac/dks533. Epub 2013 Jan 20.


Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.

Le Moing V, Thiébaut R, Chêne G, Sobel A, Massip P, Collin F, Meyohas M, Al Kaïed F, Leport C, Raffi F; ANRS CO8 (APROCO/COPILOTE) Study Group.

HIV Med. 2007 Apr;8(3):156-63.

Supplemental Content

Support Center